Search PubMed⌕ Search

Biomedical subjects

I Fogelman

Publications and source records attributed to I Fogelman.

At least 91 records · Page 5Linked to original sources

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

In the UK, over 250 000 patients take continuous oral glucocorticoids (GCs), yet no more than 14% receive any therapy to prevent bone loss, a major complication of GC treatment. Bone loss is rapid, particularly in the first year, and fracture risk may double. This review, based wherever possible on clinical evidence, aims to provide easy-to-use guidance with wide applicability. A treatment algorithm is presented for adults receiving GC doses of 7.5 mg day(-1) or more for 6 months or more. General measures, e.g. alternative GCs and routes of administration, and therapeutic interventions, e.g. cyclical etidronate and hormone replacement, are recommended.

Bone Resorption↗

Management of male osteoporosis: report of the UK Consensus Group.

Although osteoporosis is generally regarded as a disease of women, up to 30% of hip fractures and 20% of vertebral fractures occur in men. Risk factors for osteoporotic fractures in men include low body mass index, smoking, high alcohol consumption, corticosteroid therapy, physical inactivity, diseases that predispose to low bone mass, and conditions increasing the risk of falls. The key drugs and diseases that definitely produce a decrease in bone mineral density (BMD) and/or an increase in fracture rate in men are long-term corticosteroid use, hypogonadism, alcoholism and transplantation. Age-related bone loss may be a result of declining renal function, vitamin D deficiency, increased parathyroid hormone levels, low serum testosterone levels, low calcium intake and absorption. Osteoporosis can be diagnosed on the basis of radiological assessments of bone mass, or clinically when it becomes symptomatic. Various biochemical markers have been related to bone loss in healthy and osteoporotic men. Their use as diagnostic tools, however, needs further investigation. A practical approach would be to consider a bone density more than one SD below the age-matched mean value (Z < -1) as an indication for therapy. The treatment options for men with osteoporosis include agents to influence bone resorption or formation and specific therapy for any underlying pathological condition. Testosterone treatment increases BMD in hypogonadal men, and is most effective in those whose epiphyses have not closed completely. Bisphosphonates are the treatment of choice in idiopathic osteoporosis, with sodium fluoride and anabolic steroids to be used as alternatives.

Adult↗

Review of 3,530 referrals for bone density measurements of spine and femur: evidence that radiographic osteopenia predicts low bone mass.

PURPOSE: To determine the relationship between bone mineral density (BMD) measurements and the initial reason for referral to a BMD screening service. MATERIALS AND METHODS: Referral letters for 3,479 of the 3,530 women referred for BMD screening were classified according to the indication for screening. Mean age-matched standard deviation scores (Z scores) were derived for each of the 10 most common indications. Mean BMD between each group was compared with the age-matched value from the local normal range by means of a one-sample Student t test. Mean young normal standard deviation scores (T scores) were derived, and the percentages of women with osteopenia or osteoporosis from each referral group were calculated on the basis of the World Health Organization criteria. RESULTS: The most common reason for referral was to aid in a decision regarding hormone replacement therapy (n = 700). The highest proportion of women with osteoporosis in any group was in the radiographic osteopenia group (n = 269). CONCLUSION: Radiographic evidence of osteopenia is a strong predictor of osteoporosis. Screening for osteopenia appears justified in this and other high-risk groups and those seeking a rationale for preventive therapy.

Adolescent↗

Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.

PURPOSE: 99mTechnetium methylene diphosphonate (99mTc MDP) bone scintigraphy is currently the method of choice for the detection of bone metastases, but 18F-fluoro-deoxy-D-glucose positron emission tomography (18FDG PET) offers superior spatial resolution and improved sensitivity. We have compared 18FDG PET with 99mTc MDP bone scintigraphy in patients with skeletal metastases from breast cancer and have analyzed the data in subgroups based on radiographic characteristics of lesions. PATIENTS AND METHODS: Twenty-three women with breast cancer and confirmed bone metastases were studied with both 99mTC MDP bone scintigraphy and 18FDG PET, and the number of lesions detected and the quantitation of uptake (standardized uptake values [SUVs]) of 18FDG in osteolytic and osteoblastic metastases were compared. Survival was compared for both lytic and blastic bone metastases and for patients with high and low accumulation of 18FDG. RESULTS: 18FDG PET detected more lesions than 99mTc MDP scintigraphy (mean, 14.1 and 7.8 lesions, respectively; P < .01). However, 18FDG detected fewer bone metastases compared with 99mTc MDP scintigraphy in a subgroup of patients with osteoblastic disease (P < .05). Higher SUVs were observed for osteolytic than osteoblastic disease (mean, 6.77 and 0.95, respectively; P < .01). Survival was lower in patients with osteolytic disease compared with the remainder (P=.01). A difference in survival was not found for those patients with high SUVs (> 3.6; P=.4). CONCLUSION: 18FDG PET is superior to bone scintigraphy in the detection of osteolytic breast cancer metastases, which led to a poorer prognosis. In contrast, osteoblastic metastases show lower metabolic activity and are frequently undetectable by PET. The biologic explanation for this observation remains to be elucidated.

Adult↗

Morphometric X-ray absorptiometry: reference data for vertebral dimensions.

Vertebral fractures are a common and important consequence of osteoporosis and are often identified via morphometric analysis of conventional lateral spine radiographs (morphometric radiography or MRX). A new method of performing vertebral morphometry using images acquired on dual-energy X-ray absorptiometry (DXA) scanners (morphometric X-ray absorptiometry or MXA) has recently been developed. In this study, we derive reference data for vertebral heights and height ratios using MXA scans as the data source and compare the results with previously published MRX studies. One thousand and nineteen Caucasian women (mean age 63 years, range 33-86) were recruited. An MXA scan, covering 13 vertebrae from L4 to T4, was acquired for each subject on one of four DXA systems located at three centers in the U.K. Analysis of variance found statistically significant but relatively small differences among centers, machines, and scan modes, and therefore data were pooled for reference range calculations. Three vertebral heights (anterior, mid, and posterior) were measured and four ratios (wedge, mid-wedge, and two crush) calculated. These data sets were trimmed using an iterative algorithm to remove extreme values assumed to represent deformed vertebrae, then mean and SD values were calculated using the remaining data. When the data were split by age, a small but statistically significant decrease in vertebral height between the sixth and eighth decades was found, but this was not replicated for the vertebral height ratios. Marked differences were observed between MXA data and MRX, but were comparable to those between different MRX studies. These may result from differences in image quality and point placement protocols, population differences, differences in radiographic technique, and differences in the derivation of a group of "normal" vertebrae. This study suggests that reference data of vertebral dimensions should be specific to the technique which uses those data as a reference, i.e., MXA.

Absorptiometry, Photon↗

A comparison of a peripheral DXA system with conventional densitometry of the spine and femur.

Because of the perceived high cost of dual-energy X-ray absorptiometry (DXA) studies of the spine and femur, there is renewed interest in small, low-cost X-ray devices for scanning the peripheral skeleton. We have compared forearm bone mineral density (BMD) measurements (distal and ultradistal sites) performed on a DTX-200 (Osteometer MediTech, Hoersholm, Denmark) with spine (L1-L4) and femur (femoral neck and total hip sites) scans performed on a QDR-4500 (Hologic, Waltham, MA) in 172 white UK women aged 22-84 yr with a view to establishing differences caused by inconsistent reference ranges and different age-related changes in BMD. All BMDs were expressed as T-scores using the manufacturers' reference ranges for the forearm and spine, and the National Health and Nutrition Examination Survey (NHANES) ranges for the femur. Linear regression between peripheral and axial sites gave correlation coefficients r = 0.71-0.74 and roof mean standard errors (RMSE) 0.88-1.14 in T-score units. Subjects were divided into the following five age groups: <40 yr; 40-49 yr; 50-59 yr; 60-69 yr and >/=70 yr. A large systematic difference between distal and ultradistal T-scores (mean DeltaT = 0.59, SEM = 0.05) was found affecting all age groups. When the mean difference in T-score between each forearm site (distal, ultradistal) and each axial site (spine, femoral neck, total hip) was examined for premenopausal subjects (n = 58) the mean difference between forearm and axial T-score showed a consistent negative offset (DeltaT = -0.41 to -0.48) for the distal forearm site and a consistent positive offset (DeltaT = +0.30 to +0.37) for the ultradistal site. When interpreting results in postmenopausal women, age-related T-score changes in the forearm were in close agreement with the femoral neck region of exterest (ROI), but systematic differences were found between the forearm and the spine and total hip sites. The two forearm and three axial sites were compared to evaluate the number of postmenopausal subjects identified as osteoporotic on the basis of the World Health Organization (WHO) Study Group criteria (T-score <-2.5). Although forearm and spine T-scores identified approximately equal numbers of subjects as osteoporotic (distal 38/114; ultradistal 31/114; spine 30/114), the two femur sites identified fewer subjects as osteoporotic (femoral neck 25/114; total hip 16/114). The number for the total hip site was statistically significantly smaller than the spine and forearm sites.

Journal Article↗

[11C]Methionine positron emission tomography for patients with persistent or recurrent hyperparathyroidism after surgery.

OBJECTIVE: Reoperation in patients with recurrent hyperparathyroidism usually requires localisation of abnormal glands. Current imaging techniques are not always successful in this group of patients. An evaluation of [11C]methionine positron emission tomography (PET) has been made to assess the ability of the technique to localise abnormal glands in patients with hyperparathyroidism after previous surgery. SUBJECTS AND METHODS: Eight patients (five with primary, and three with tertiary hyperparathyroidism) who had undergone one to three previous surgical explorations were studied. [11C]methionine PET scans of the neck and mediastinum were performed in all patients. All had recent technetium-99m (99mTc)-labelled sestamibi (n = 7) or thallium-201 (201Tl)/99mTc subtraction (n = 1) parathyroid scans available for comparison. Subsequent surgical correlation was available in all cases. RESULTS: [11C]methionine PET correctly located an abnormal site of uptake in all five patients with primary hyperparathyroidism compared with only one when conventional nuclear medicine methods were used. In the patients with tertiary hyperparathyroidism, [11C]methionine PET correctly located one, confirmed the absence of cervical or mediastinal abnormality in a patient with an autotransplanted forearm autonomous gland, and failed to demonstrate an abnormality in a third. 99mTc-labelled sestamibi scans were negative in all three patients. CONCLUSION: [11C]methionine PET correctly locates abnormal parathyroid glands in the majority of patients with persistent or recurrent hyperparathyroidism after surgery in whom conventional non-invasive nuclear medicine imaging has failed.

Adenoma↗

Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG.

UNLABELLED: Technetium-99m HL91 is a potential agent for imaging hypoxic tissue in vivo. A pilot evaluation using a prototype formulation assessed efficacy in tumor imaging and compared results with 18F-fluorodeoxyglucose (FDG) PET. METHODS: Ten patients with malignant tumors were included. Tumors included carcinoma of the bronchus (n = 3), carcinoma of the thyroid (n = 2), lymphoma (n = 2), soft tissue sarcoma (n = 1), carcinoid (n = 1) and carcinoma of the breast (n = 1). Whole-body planar scans and localized SPECT scans were performed at 1 and 4 hr postinjection of 600 MBq 99mTc HL91. Half-body and localized emission/transmission 18F-FDG PET scans were performed 60 min postinjection 370 MBq 18F-FDG in eight patients. Lesion-to-normal tissue background ratios were measured for all 99mTc HL91 and 18F-FDG PET scans and percentage uptake and standardized uptake values measured for 99mTc HL91 and 18F-FDG PET, respectively. RESULTS: Technetium-99m HL91 showed visible uptake into the tumor area in all seven studies where the tumor was clearly identified by 18F-FDG PET; 99mTc HL91 uptake was not detected in one study (carcinoid) in which 18F-FDG was weakly positive. Two further tumors, in which PET correlation was not available, showed accumulation of 99mTc HL91. In two 99mTc HL91 studies, abnormality was apparent only on SPECT images. Lesion-to-normal tissue background ratios for 99mTc HL91 ranged from 1.22/2.53 at 1 hr and 1.33/2.89 at 4 hr on planar images and 1.23/5.2 and 1.67/14.6 on SPECT images, respectively. CONCLUSION: In this study, the use of 99mTc HL91 resulted in uptake in the majority of malignant tumors identified by 18F-FDG-PET. Technetium-99m HL91 exhibits good imaging characteristics, with imaging at 4 hr providing good lesion-to-normal tissue background ratios, that are further enhanced by SPECT.

Aged↗

Screening for osteopenia and osteoporosis: do the accepted normal ranges lead to overdiagnosis?

Osteoporosis is a common disease which causes significant morbidity and mortality and in many cases may be preventable. In the absence of fragility fractures the accepted method of identifying those at high risk is based upon bone mineral density (BMD) measurements with defined cut-off points. To correctly delineate normal from abnormal, reliable reference ranges appropriate to the observed population are required. We have studied the age-dependent changes in mean BMD and standard deviation at the lumbar spine and femoral neck in a normal population extracted from 4280 women screened for osteopenia and compared our findings with the manufacturer's normal range (MNR). The recent World Health Organization criteria for the diagnosis of osteopenia and osteoporosis using the 'manufacturer's young normal' (MYN) values and our 'study young normal' (SYN) values have been applied. The study normal population (SNP) included 2068 women (mixed social class; mean age 53 years, range 30-79 years). The distribution of mean lumbar spine BMD with age in SNP was generally similar to the MNR. In contrast mean femoral neck bone density from SNP was significantly different from the MNR, ranging from 3% to 12% lower in each 5-year group analysed (p < 0.05). Comparison of standard deviations in spine BMD in SNP against the fixed MNR standard deviation showed a statistically significant increase commencing at 45 years of age. The magnitude of this increase appeared to rise with age and remained significant in the 75- to 79-year age group (p < 0.05). In contrast, standard deviation in femoral neck BMD in SNP appeared relatively constant with age except in the group of women at and around the time of the menopause. The SYN value for mean lumbar spine BMD was 0.994 g/cm2 (cf. MYN value 1.047, p < 0.0001) with a standard deviation of 0.122 g/cm2 (cf. MYN 0.11, p = 0.0005). Similarly our SYN value for femoral neck BMD was 0.787 (cf. MYN value 0.895, p < 0.0001) with a standard deviation of 0.109 (cf. MYN value 0.10, p = 0.0027). Using SYN values 36% (748) for the spine and 33% (675) for the hip of our normal population are classified as osteopenic or osteoporotic. Using MYN values increases the proportion of women classified as osteopenic or osteoporotic to 52% (1078) for the spine and 68% (1409) for the femur. If both sites of measurement are considered simultaneously SYN classifies 46% (952) as either osteopenic or osteoporotic at one or other site, which is increased to 73% (1513) when the MYN values are used. We observe that manufacturer's reference ranges may not be appropriate for the local population and may lead to an erroneously high diagnosis of osteopenia and osteoporosis, which would lead to unnecessary patient anxiety and perhaps errors regarding treatment.

Adult↗

The effect of weight change on DXA scans in a 2-year trial of etidronate therapy.

Variation in soft tissue composition is a potential cause of error in dual X-ray absorptiometry (DXA) measurements of bone mineral density (BMD). We investigated the effect of patients' change of weight on DXA scans in 152 women enrolled in a 2-year trial of cyclical etidronate therapy. Scans of the spine, hip, and total body were performed at baseline, 1 and 2 years on a Hologic QDR-2000. The study was completed by 135 subjects (64 on etidronate, 71 on placebo). Results were expressed as the percentage change in BMD (spine, femoral neck, total body) or bone mineral content (BMC)(total body only) at 2 years. Total body scans were analyzed using the manufacturer's 'standard' and 'enhanced' algorithms. Analysis was performed using multivariate regression with percentage change in BMD or BMC as the dependent variable, and treatment group and percentage change in weight as the independent variables. Weight change varied between -14.4% and +16.7%. All DXA variables showed a statistically significant treatment effect. Standard total body BMD and BMC and enhanced total body BMC all showed a significant dependence on weight change (P < 0.01, P < 0.001 and P < 0.01, respectively). No effect of weight change was seen on spine, femoral neck, or enhanced total body BMD. In order to investigate the effects of weight on long-term precision, patients were allocated to two groups according to baseline body mass index (BMI < 25 and > 25 kg/m2, respectively). For femoral neck BMD the root mean square (RMS) residual percentage change was statistically significantly larger in the high BMI group (P < 0.05) but all other bone density variables showed no significant difference. With patients allocated to two groups according to their absolute percentage change in weight (< 5% and > 5%, respectively) the RMS residual percentage changes in the bone density variables were statistically significantly larger in the large weight change group for femoral neck BMD (P < 0.05) and for standard and enhanced total body BMC (P < 0.01 and P < 0.05, respectively). With the exception of the standard total body algorithm, weight change in a longitudinal study of postmenopausal women was not found to cause systematic errors in the results of DXA studies but may adversely affect precision.

Absorptiometry, Photon↗

Technical principles of dual energy x-ray absorptiometry.

Since its introduction nearly ten years ago, dual-energy x-ray absorptiometry (DXA) has become the single most widely used technique for performing bone densitometry studies. One reason for its popularity is the ability of DXA systems to measure bone mineral density (BMD) in the spine and proximal femur, the two most common sites for osteoporotic fractures. Other advantages of DXA include the exceptionally low radiation dose to patients, short scan times, high resolution images, good precision and inherent stability of calibration. For these reasons DXA scans are widely used to diagnose osteoporosis, assist making decisions in treatment, and as a follow-up response to therapy. Another important application has been the use of DXA in many clinical trials of new treatments for osteoporosis. Since the first generation pencil beam DXA systems became available, the most significant technical innovation has been the introduction of fan beam systems with shorter scan times, increased patient throughput, and improved image quality. New clinical applications include the measurement of lateral spine and total body BMD, body composition, and vertebral morphometry. Despite these advances, posteroanterior (PA) spine and proximal femur scans remain the most widely used application because of their utility in treatment decisions and monitoring response to therapy.

Absorptiometry, Photon↗

Interpretation of bone densitometry studies.

Dual-energy x-ray absorptiometry (DXA) is widely used for identifying patients with osteoporosis, making decisions about the commencement of preventive therapy, and following up response to treatment. It is important that radiologists and nuclear medicine physicians issuing clinical reports present clear interpretations that aid the primary care physician in making decisions affecting treatment. This review discusses the principles behind the interpretation of bone mineral density (BMD) studies. After a World Health Organization report published in 1994, osteoporosis is often diagnosed on the basis of the patient's T-score value (difference of BMD from young adult mean normalized to the population SD). T-scores are a measure of current fracture risk. There are problems relating to the use of T-scores in the elderly, and we argue that decisions about treatment are generally best made on the basis of the Z-score value (difference of BMD from age-matched mean normalized to the population SD) because this measures the patient's fracture risk relative to his or her peers. Recent studies confirm that the posteroanterior (PA) projection lumbar spine scan is still the optimum measurement site for monitoring response to treatment. A BMD change of 4.5% is required to register a statistically significant change.

Absorptiometry, Photon↗

Vertebral morphometry studies using dual-energy x-ray absorptiometry.

Vertebral fractures are one of the most common consequences of osteoporosis. They are usually diagnosed by visual interpretation of lateral radiographs of the lumbar and thoracic spine. Vertebral morphometry, based on measurements of the anterior, middle, and posterior heights of the vertebral bodies from T4 to L4, is a useful adjunct to the visual reading of radiographs. A new generation of dual-energy x-ray absorptiometry (DXA) scanners offers software for acquiring lateral images of the spine and performing vertebral morphometry analysis. Advantages of DXA morphometry include straightforward and reproducible patient positioning, absence of geometrical distortion of the image, low radiation dose, digital acquisition, and simplified, semi-automated scan analysis. The widespread availability of such DXA systems should make the investigation of vertebral fractures more widely accessible.

Absorptiometry, Photon↗